Doctor of Optometry Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Diana Gilbert

Optometrist West Chester, OH Doctor of Optometry

NPI 1003816950 CMS profile 391642

8629 N Pavillion, West Chester, OH 45069

Open in the dashboard

General payments

$1,842

47 records reported · program years 2019–2024

Research payments

$60,375

Paid to them · 5 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Diana Gilbert of West Chester, OH is reported in the CMS Open Payments database as having received $1,842 across 47 general payments and $60,375 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $116 3
2023 General $267 9
2022 General $481 10
2021 General $452 12
2020 General $155 3
2019 General $372 10
2019 Research $60,375 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diana Gilbert
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Diana Gilbert were reported at $0. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Diana Gilbert Optometrist median Middle half National median
2019 $372 $159 $67–$371 $163
2020 $155 $72 $29–$165 $114
2021 $452 $125 $46–$292 $132
2022 $481 $162 $66–$374 $149
2023 $267 $177 $72–$406 $160
2024 $116 $188 $77–$427 $164
2025 $0 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Johnson & Johnson Vision Care, Inc. $533 8 payments
  2. CooperVision Inc. $460 12 payments
  3. Alcon Vision LLC $280 9 payments
  4. Sun Pharmaceutical Industries Inc. $159 4 payments
  5. Allergan Inc. $94 2 payments
  6. AbbVie, Inc. $77 3 payments
  7. Marco Ophthalmic, Inc. $64 2 payments
  8. Optos, Inc. $57 1 payment
  9. Kala Pharmaceuticals, Inc. $41 2 payments
  10. Bausch & Lomb Americas Inc. $41 2 payments
  11. Other $36 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,785 46 payments
  2. Entertainment $57 1 payment
Products named General payments · program years 2019–2024
  1. Acuvue $533 8 payments
  2. Multiple Brands Contact Lens $276 6 payments
  3. Cequa $159 4 payments
  4. MyDay Contact Lens $141 4 payments
  5. RESTASIS MULTIDOSE $120 3 payments
  6. EYSUVIS $113 1 payment
  7. Precision 1 $97 2 payments
  8. VUITY $77 3 payments
  9. P200DTx $57 1 payment
  10. P200T $57 1 payment
  11. Other $450 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Bausch Health US, LLC $60,375 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

171

Median for Optometry: 120

Drug cost

$28,106

Median for Optometry: $8,864

Branded share of claims

24%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 14 $24,906
Loteprednol Etabonate Generic 12 $1,398
Latanoprost Generic 76 $608
Prednisolone Acetate Generic 15 $488
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 11 $307
Bacitracin-Polymyxin Bacitracin/Polymyxin B Sulfate Brand 16 $230
Brimonidine Tartrate Generic 13 $168
Timolol Maleate Generic 14 $0

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$15,692

Medicare's payments for the services billed

Medicare patients

150

Average age 75

Services billed

250

85 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Diabetes 37%
Ischemic heart disease 30%
Chronic kidney disease 21%
Atrial fibrillation 17%
Heart failure 15%
Osteoporosis 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record